Trader consensus on no new coronavirus pandemic in 2026 reflects persistently low SARS-CoV-2 circulation, with WHO reporting just 1.2% test positivity globally in May 2026 and CDC data showing declining or stable infections across 38 U.S. states as of early June. Endemic Omicron subvariants such as BA.3.2 circulate at low prevalence (under 0.2% in U.S. sequences) without evidence of enhanced transmissibility or severity sufficient to overwhelm immunity. Broad population-level protection from prior exposures and vaccines continues to limit severe outcomes, keeping emergency department visits for COVID-19 at 0.1%. Realistic challenges include undetected zoonotic spillovers or rapid evolution enabling immune escape, though current genomic surveillance and reproductive number estimates near 1.0 indicate no near-term shift toward pandemic conditions.